David Hochman, CEO and Founder, Orchestra BioMed is bringing a partnership model to promote healthcare innovation particularly in the field of drug eluting balloons. Their lead product Virtue Sirolimus Angiofusion Balloon (SAB) is delivering an established therapeutic agent in interventional cardiology during balloon angioplasty without needing a stent permanent implant. This unique drug delivery solution encapsulates the drug in a balloon that has no coating and delivers the drug through micropores in the balloon to deliver the intended dose.